Recommendations
ACC/AHA/SCAI PCI Guidelines - British Cardiovascular Intervention ...
ACC/AHA/SCAI PCI Guidelines - British Cardiovascular Intervention ...
- No tags were found...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
ACC - www.acc.org<br />
AHA - www.americanheart.org<br />
SCAI - www.scai.org<br />
Smith et al. 2005<br />
ACC/AHA/SCAI Practice Guidelines<br />
115<br />
in elective coronary stenting: results of a randomized trial. J<br />
Invasive Cardiol 2002;14:72-9.<br />
713. Tcheng JE, Harrington RA, Kottke-Marchant K, et al.<br />
Multicenter, randomized, double-blind, placebo-controlled trial of<br />
the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in<br />
elective coronary intervention. IMPACT Investigators.<br />
Circulation 1995;91:2151-7.<br />
714. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate<br />
and reversible platelet inhibition after intravenous administration<br />
of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous<br />
coronary intervention. Am J Cardiol 1995;76:1222-7.<br />
715. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on<br />
adverse cardiac events in patients with unstable angina or acute<br />
myocardial infarction undergoing coronary angioplasty: the<br />
RESTORE Investigators. Randomized Efficacy Study of<br />
Tirofiban for Outcomes and Restenosis. Circulation 1997;96:<br />
1445-53.<br />
716. Gibson CM, Goel M, Cohen DJ, et al. Six-month angiographic<br />
and clinical follow-up of patients prospectively randomized to<br />
receive either tirofiban or placebo during angioplasty in the<br />
RESTORE trial. Randomized Efficacy Study of Tirofiban for<br />
Outcomes and Restenosis. J Am Coll Cardiol 1998;32:28-34.<br />
717. Kereiakes DJ, Kleiman NS, Ambrose J, et al. Randomized, double-blind,<br />
placebo-controlled dose-ranging study of tirofiban<br />
(MK-383) platelet IIb/IIIa blockade in high risk patients undergoing<br />
coronary angioplasty. J Am Coll Cardiol 1996;27:536-42.<br />
718. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ.<br />
Abciximab reduces mortality in diabetics following percutaneous<br />
coronary intervention. J Am Coll Cardiol 2000;35:922-8.<br />
719. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein<br />
IIb/IIIa inhibitors reduce mortality in diabetic patients with non-<br />
ST-segment-elevation acute coronary syndromes. Circulation<br />
2001;104:2767-71.<br />
720. Peerlinck K, De Lepeleire I, Goldberg M, et al. MK-383 (L-<br />
700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa<br />
antagonist, is active in man. Circulation 1993;88:1512-7.<br />
721. Kereiakes DJ, Midei M, Hermiller J, et al. Procedural and late<br />
outcomes following MULTI-LINK DUET coronary stent deployment.<br />
Am J Cardiol 1999;84:1385-90.<br />
722. Barr E, Snapinn SM, Sax FL, Theroux P. Improved Long-Term<br />
Clinical Outcomes in Unstable Angina Patients Undergoing<br />
Coronary Angioplasty Following Therapy With Tirofiban and<br />
Heparin (abstr). J Am Coll Cardiol 1998;31:55A.<br />
723. Topol EJ, Bonan R, Jewitt D, et al. Use of a direct antithrombin,<br />
hirulog, in place of heparin during coronary angioplasty.<br />
Circulation 1993;87:1622-9.<br />
724. Grayburn PA, Willard JE, Brickner ME, Eichhorn EJ. In vivo<br />
thrombus formation on a guidewire during intravascular ultrasound<br />
imaging: evidence for inadequate heparinization. Cathet<br />
Cardiovasc Diagn 1991;23:141-3.<br />
725. Dougherty KG, Gaos CM, Bush HS, Leachman DR, Ferguson JJ.<br />
Activated clotting times and activated partial thromboplastin<br />
times in patients undergoing coronary angioplasty who receive<br />
bolus doses of heparin. Cathet Cardiovasc Diagn 1992;26:260-3.<br />
726. Bowers J, Ferguson JJ3. The use of activated clotting times to<br />
monitor heparin therapy during and after interventional procedures.<br />
Clin Cardiol 1994;17:357-61.<br />
727. Ferguson JJ. All ACTs are not created equal (editorial). Texas<br />
Heart Inst J 1992;19:1-3.<br />
728. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy<br />
during extracorporeal circulation. I. Problems inherent in existing<br />
heparin protocols. J Thorac Cardiovasc Surg 1975;69:674-84.<br />
729. Young JA, Kisker CT, Doty DB. Adequate anticoagulation during<br />
cardiopulmonary bypass determined by activated clotting time<br />
and the appearance of fibrin monomer. Ann Thorac Surg<br />
1978;26:231-40.<br />
730. Schiele F, Vuillemenot A, Kramarz P, et al. Use of recombinant<br />
hirudin as antithrombotic treatment in patients with heparininduced<br />
thrombocytopenia. Am J Hematol 1995;50:20-5.<br />
731. Brack MJ, More RS, Hubner PJ, Gershlick AH. The effect of low<br />
dose nitroglycerin on plasma heparin concentrations and activated<br />
partial thromboplastin times. Blood Coagul Fibrinolysis<br />
1993;4:183-6.<br />
732. Habbab MA, Haft JI. Heparin resistance induced by intravenous<br />
nitroglycerin: a word of caution when both drugs are used concomitantly.<br />
Arch Intern Med 1987;147:857-60.<br />
733. Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, Marsh KC,<br />
Leachman DR. Relation between procedural activated coagulation<br />
time and outcome after percutaneous transluminal coronary<br />
angioplasty. J Am Coll Cardiol 1994;23:1061-5.<br />
734. Narins CR, Hillegass WBJ, Nelson CL, et al. Relation between<br />
activated clotting time during angioplasty and abrupt closure.<br />
Circulation 1996;93:667-71.<br />
735. Frierson JH, Dimas AP, Simpfendorfer CC, Pearce G, Miller M,<br />
Franco I. Is aggressive heparinization necessary for elective<br />
PTCA? Cathet Cardiovasc Diagn 1993;28:279-82.<br />
736. Popma JJ, Satler LF, Pichard AD, et al. Vascular complications<br />
after balloon and new device angioplasty. Circulation 1993;88:<br />
1569-78.<br />
737. Boccara A, Benamer H, Juliard JM, et al. A randomized trial of a<br />
fixed high dose versus a weight-adjusted low dose of intravenous<br />
heparin during coronary angioplasty. Eur Heart J 1997;18:631-5.<br />
738. Tolleson TR, O’shea JC, Bittl JA, et al. Relationship between<br />
heparin anticoagulation and clinical outcomes in coronary stent<br />
intervention: observations from the ESPRIT trial. J Am Coll<br />
Cardiol 2003;41:386-93.<br />
739. Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE,<br />
Topol EJ. Relationship between activated clotting time and<br />
ischemic or hemorrhagic complications: analysis of 4 recent randomized<br />
clinical trials of percutaneous coronary intervention.<br />
Circulation 2004;110:994-8.<br />
740. Friedman HZ, Cragg DR, Glazier SM, et al. Randomized<br />
prospective evaluation of prolonged versus abbreviated intravenous<br />
heparin therapy after coronary angioplasty. J Am Coll<br />
Cardiol 1994;24:1214-9.<br />
741. Fail PS, Maniet AR, Banka VS. Subcutaneous heparin in postangioplasty<br />
management: comparative trial with intravenous<br />
heparin. Am Heart J 1993;126:1059-67.<br />
742. Kong DF, Califf RM. Post-procedure heparin: boon or burden?<br />
Am Heart J 1998;136:183-5.<br />
743. Garachemani AR, Kaufmann U, Fleisch M, Meier B. Prolonged<br />
heparin after uncomplicated coronary interventions: a prospective,<br />
randomized trial. Am Heart J 1998;136:352-6.<br />
744. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated<br />
heparin in high-risk patients with non-ST-segment elevation<br />
acute coronary syndromes managed with an intended early<br />
invasive strategy: primary results of the SYNERGY randomized<br />
trial. JAMA 2004;292:45-54.<br />
744a.Lincoff AM, Kleiman NS, Kereiakes D, et al. Long-term efficacy<br />
of bivalirudin and provisional glycoprotein IIb/IIIa blockade<br />
vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous<br />
coronary intervention: REPLACE-2 Randomized Trial.<br />
JAMA 2004;292:696-703.<br />
745. Maroo A, Lincoff AM. Bivalirudin in PCI: an overview of the